19.52
+0.39(+2.04%)
Currency In USD
| Previous Close | 19.13 |
| Open | 19.28 |
| Day High | 19.54 |
| Day Low | 19.15 |
| 52-Week High | 26.58 |
| 52-Week Low | 19.05 |
| Volume | 1.24M |
| Average Volume | 1.47M |
| Market Cap | 2.39B |
| PE | 11.83 |
| EPS | 1.65 |
| Moving Average 50 Days | 20.41 |
| Moving Average 200 Days | 22.18 |
| Change | 0.39 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $6,256.41 as of September 29, 2025 at a share price of $19.52. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $6,081 as of September 29, 2025 at a share price of $19.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire Inc.
Aug 26, 2025 11:12 PM GMT
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-s
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire Inc.
Aug 25, 2025 12:03 PM GMT
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-sta
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
GlobeNewswire Inc.
Aug 06, 2025 12:03 PM GMT
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagno